Maxim Group Reaffirms Their Buy Rating on Agile Therapeutics (AGRX)

Maxim Group analyst Naz Rahman reiterated a Buy rating on Agile Therapeutics (AGRXResearch Report) yesterday and set a price target of $1.00. The company’s shares closed yesterday at $0.57.

According to TipRanks, Rahman is an analyst with an average return of -28.0% and a 25.86% success rate. Rahman covers the Healthcare sector, focusing on stocks such as Vertex Pharmaceuticals, 9 Meters Biopharma, and Galmed Pharmaceuticals.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Agile Therapeutics with a $3.00 average price target, a 430.97% upside from current levels. In a report released yesterday, H.C. Wainwright also reiterated a Buy rating on the stock with a $5.00 price target.

See the top stocks recommended by analysts >>

AGRX market cap is currently $22.05M and has a P/E ratio of -0.03.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Agile Therapeutics, Inc. is a healthcare company, which engages in the development and commercialization of transdermal patch. Its lead product candidate, Twirla, also known as AG200-15, is an investigational low-dose, non-daily prescription contraceptive. The company was founded by Chien Te Yen on December 22, 1997 and is headquartered in Princeton, NJ.

Read More on AGRX:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More